Clinical Trial Update: Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer [Phase 1]

View source ↗

Summary

Amgen is evaluating Xaluritamig in a Phase 1 neoadjuvant trial for localized prostate cancer, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xaluritamig (Xaluritamig)

Snippet

Sponsor: Amgen | Conditions: Prostate Cancer | Phase 1 | Status: RECRUITING